Pharmacology of Pimasertib, A Selective MEK1/2 Inhibitor
- PMID: 29488172
- DOI: 10.1007/s13318-018-0466-x
Pharmacology of Pimasertib, A Selective MEK1/2 Inhibitor
Abstract
Pimasertib belongs to the growing family of mitogen activated protein kinase (MEK1/2) inhibitors undergoing clinical development for various cancer indications. Since the MEK inhibition in several cell signalling transduction cascades within tumours was considered therapeutically beneficial, number of clinical investigations of pimasertib have been reported. Despite being orally bioavailable in cancer patients, pimasertib undergoes faster clearance with a short elimination half-life. In addition, due to occurrence of toxicity, the development of pimasertib appears to be stalled. Case studies are provided on the possible utilization of pimasertib in combination therapies with other approved drugs. Based on the review, it appeared that there was the need to identify the optimal dose and the dosing regimen of pimasertib to provide a balance between safety and efficacy when combined with approved therapies.
Similar articles
-
Metabolism of the MEK1/2 Inhibitor Pimasertib Involves a Novel Conjugation with Phosphoethanolamine in Patients with Solid Tumors.Drug Metab Dispos. 2017 Feb;45(2):174-182. doi: 10.1124/dmd.116.072934. Epub 2016 Dec 1. Drug Metab Dispos. 2017. PMID: 27934635 Clinical Trial.
-
Pimasertib, a selective oral MEK1/2 inhibitor: absolute bioavailability, mass balance, elimination route, and metabolite profile in cancer patients.Br J Clin Pharmacol. 2016 Dec;82(6):1498-1508. doi: 10.1111/bcp.13078. Epub 2016 Sep 19. Br J Clin Pharmacol. 2016. PMID: 27483391 Free PMC article. Clinical Trial.
-
Antitumor activity of a combination of dual PI3K/mTOR inhibitor SAR245409 and selective MEK1/2 inhibitor pimasertib in endometrial carcinomas.Gynecol Oncol. 2015 Aug;138(2):323-31. doi: 10.1016/j.ygyno.2015.05.031. Epub 2015 May 29. Gynecol Oncol. 2015. PMID: 26033306
-
MEK1/2 inhibitors in the treatment of gynecologic malignancies.Gynecol Oncol. 2014 Apr;133(1):128-37. doi: 10.1016/j.ygyno.2014.01.008. Epub 2014 Jan 14. Gynecol Oncol. 2014. PMID: 24434059 Review.
-
MEK 1/2 inhibitors in the treatment of hepatocellular carcinoma.Expert Rev Gastroenterol Hepatol. 2015 Jul;9(7):993-1003. doi: 10.1586/17474124.2015.1040763. Epub 2015 Apr 27. Expert Rev Gastroenterol Hepatol. 2015. PMID: 25915713 Review.
Cited by
-
A genome-scale CRISPR knock-out screen in chronic myeloid leukemia identifies novel drug resistance mechanisms along with intrinsic apoptosis and MAPK signaling.Cancer Med. 2020 Sep;9(18):6739-6751. doi: 10.1002/cam4.3231. Epub 2020 Jul 28. Cancer Med. 2020. PMID: 38831555 Free PMC article.
-
Synergistic inhibition of MEK and reciprocal feedback networks for targeted intervention in malignancy.Cancer Biol Med. 2019 Aug;16(3):415-434. doi: 10.20892/j.issn.2095-3941.2019.0137. Cancer Biol Med. 2019. PMID: 31565475 Free PMC article.
-
Azelnidipine inhibits esophageal squamous cell carcinoma proliferation in vivo and in vitro by targeting MEK1/2.Mol Ther Oncolytics. 2022 Sep 26;27:61-72. doi: 10.1016/j.omto.2022.09.007. eCollection 2022 Dec 15. Mol Ther Oncolytics. 2022. PMID: 36284716 Free PMC article.
-
Phosphorylation Sites in Protein Kinases and Phosphatases Regulated by Formyl Peptide Receptor 2 Signaling.Int J Mol Sci. 2020 May 27;21(11):3818. doi: 10.3390/ijms21113818. Int J Mol Sci. 2020. PMID: 32471307 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
